002550 千红制药
已收盘 05-18 15:00:00
资讯
新帖
简况
股市必读：千红制药（002550）5月18日董秘有最新回复
证券之星 · 01:15
股市必读：千红制药（002550）5月18日董秘有最新回复
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
证券之星 · 05-18 15:06
千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务
千红制药：原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一
证券之星 · 05-18 15:03
千红制药：原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一
千红制药：主要聚焦危重症靶向蛋白药这一关键领域开展联合攻关
证券之星 · 05-18 11:36
千红制药：主要聚焦危重症靶向蛋白药这一关键领域开展联合攻关
千红制药：公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订
证券之星 · 05-18 11:30
千红制药：公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订
千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%
证券之星 · 05-14
千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%
股市必读：千红制药（002550）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：千红制药（002550）5月8日董秘有最新回复
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
证券之星 · 05-08
千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 05-08
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
东海证券：给予千红制药买入评级
证券之星 · 05-08
东海证券：给予千红制药买入评级
千红制药（002550）披露2025年度报告网上说明会公告，5月6日股价上涨2.71%
证券之星 · 05-06
千红制药（002550）披露2025年度报告网上说明会公告，5月6日股价上涨2.71%
千红制药：公司不存在应披露而未披露的重大事项
证券之星 · 05-06
千红制药：公司不存在应披露而未披露的重大事项
股市必读：千红制药（002550）4月29日董秘有最新回复
证券之星 · 04-30
股市必读：千红制药（002550）4月29日董秘有最新回复
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
21世纪经济报道 · 04-27
30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧
千红制药：公司可转债项目尚处于有序推进过程中
证券之星 · 04-27
千红制药：公司可转债项目尚处于有序推进过程中
股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%
证券之星 · 04-27
股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%
千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%
证券之星 · 04-24
千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%
千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%
智通财经 · 04-23
千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 04-23
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
证券之星 · 04-20
千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中
加载更多
公司概况
公司名称：
常州千红生化制药股份有限公司
所属行业：
医药制造业
上市日期：
2011-02-18
主营业务：
常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。
发行价格：
32.00
{"stockData":{"symbol":"002550","market":"SZ","secType":"STK","nameCN":"千红制药","latestPrice":6.77,"timestamp":1779087789000,"preClose":6.92,"halted":0,"volume":12167000,"delay":0,"changeRate":-0.0217,"floatShares":941000000,"shares":1280000000,"eps":0.2523,"marketStatus":"已收盘","change":-0.15,"latestTime":"05-18 15:00:00","open":6.88,"high":6.88,"low":6.75,"amount":82686400,"amplitude":0.0188,"askPrice":6.77,"askSize":40,"bidPrice":6.76,"bidSize":803,"shortable":0,"etf":0,"ttmEps":0.2523,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779154200000},"marketStatusCode":5,"adr":0,"adjPreClose":6.92,"symbolType":"stock","openAndCloseTimeList":[[1779067800000,1779075000000],[1779080400000,1779087600000]],"highLimit":7.61,"lowLimit":6.23,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1279800000,"isCdr":false,"pbRate":3.1,"roa":"--","peRate":26.833135,"roe":"3.03%","epsLYR":0.32,"committee":0.106048,"marketValue":8664000000,"turnoverRate":0.0129,"status":1,"floatMarketCap":6372000000},"requestUrl":"/m/hq/s/002550","defaultTab":"news","newsList":[{"id":"2636008542","title":"股市必读：千红制药（002550）5月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2636008542","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636008542?lang=zh_cn&edition=full","pubTime":"2026-05-19 01:15","pubTimestamp":1779124511,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，千红制药报收于6.77元，下跌2.17%，换手率1.29%，成交量12.17万手，成交额8268.64万元。董秘： 尊敬的投资者，您好，公司创新药相关进展需严格遵循法规披露要求，公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订，具体修订内容详见公司相关公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900001852.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636760047","title":"千红制药：公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2636760047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636760047?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:06","pubTimestamp":1779087976,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：按规定公司收到问询函是要在2天内公告的！为什么公司拖了差不多一个月股民才在回复中知道此事？请详细解答该疑问？千红制药回复：尊敬的投资者，您好，公司严格按照证监会及交易所关于问询函回复的相关规定履行信息披露义务，依据监管要求进行了科学合理的工作安排并及时公告，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800015559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636047737","title":"千红制药：原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2636047737","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636047737?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:03","pubTimestamp":1779087792,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药05月18日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，根据公司2025年11月披露的可转债项目相关公告，公司原创一类新药QHRD106注射液三期临床研究及上市注册项目为本次可转债募投项目之一，目前该项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800015547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636465860","title":"千红制药：主要聚焦危重症靶向蛋白药这一关键领域开展联合攻关","url":"https://stock-news.laohu8.com/highlight/detail?id=2636465860","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636465860?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:36","pubTimestamp":1779075388,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，请问贵公司与中科院生物物理研究生共建的“危重症靶向蛋白药联合实验室”主要研发内容有哪些？千红制药回复：尊敬的投资者，您好，公司与中国科学院生物物理研究所大分子国家重点实验室合作共建联合实验室，主要聚焦危重症靶向蛋白药这一关键领域开展联合攻关，感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800012790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046386","title":"千红制药：公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046386","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636046386?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:30","pubTimestamp":1779075032,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月18日在投资者关系平台上答复投资者关心的问题。投资者提问：王董为什么不解释清楚同一个创新药却是两个临床试验代号两种自相矛盾的临床进度？还有公司是否确定2025年的可转换债券项目是2024年版本的修订版？千红制药回复：尊敬的投资者，您好，公司创新药相关进展需严格遵循法规披露要求，公司可转债项目于2025年11月召开董事会对可转债预案及相关文件进行了修订，具体修订内容详见公司相关公告。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800012378.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635746638","title":"千红制药（002550）披露2025年度股东会决议公告，5月14日股价下跌1.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635746638","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635746638?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:47","pubTimestamp":1778770030,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，千红制药报收于6.97元，较前一交易日下跌1.13%，最新总市值为89.2亿元。该股当日开盘7.09元，最高7.09元，最低6.96元，成交额达8452.93万元，换手率为1.28%。近日，千红制药发布《2025年度股东会决议公告》。公告显示，公司于2026年5月14日召开2025年度股东会，会议由董事会召集，董事长王耀方主持，采用现场与网络投票相结合方式召开。出席会议的股东及授权代表共513名，代表有表决权股份总数的41.1970%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400043330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634426396","title":"股市必读：千红制药（002550）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634426396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634426396?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:48","pubTimestamp":1778438894,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，千红制药报收于7.09元，下跌0.28%，换手率1.25%，成交量11.77万手，成交额8346.92万元。当日关注点来自交易信息汇总：5月8日主力资金净流出608.31万元，散户资金净流入720.8万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100001330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633106487","title":"千红制药：公司严格按照证监会和交易所的相关规定履行信息披露义务","url":"https://stock-news.laohu8.com/highlight/detail?id=2633106487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633106487?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:07","pubTimestamp":1778224034,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药05月08日在投资者关系平台上答复投资者关心的问题。为什么公司的信披那么不透明甚至隐瞒呢？公司创新药项目均处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800021282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633248729","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2633248729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633248729?lang=zh_cn&edition=full","pubTime":"2026-05-08 15:04","pubTimestamp":1778223862,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月08日在投资者关系平台上答复投资者关心的问题。投资者提问：请问宁独董:公司在2025年中期报告关于106创新药进展的描述中明确写道该药已完成期临床，但现实是该药却要做期b的补充临床验证，这是不是夸大临床进度误导投资者？作为独立董事有没有尽职做到监督作用？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800021238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633101326","title":"东海证券：给予千红制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2633101326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633101326?lang=zh_cn&edition=full","pubTime":"2026-05-08 08:35","pubTimestamp":1778200535,"startTime":"0","endTime":"0","summary":"东海证券股份有限公司杜永宏,付婷近期对千红制药进行研究并发布了研究报告《公司简评报告：业绩短期放缓，期待创新转型成果》，给予千红制药买入评级。河南千牧已正式投产，为公司提供充足的肝素上游原材料，湖北千红药用酶原料药基地已竣工，支撑胰激肽原酶、弹性蛋白酶等核心制剂规模化生产。QHRD211注射液是重组人生长激素，目前已完成II期临床患者入组。公司主营业务整体稳健，维持“买入”评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800007569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633318317","title":"千红制药（002550）披露2025年度报告网上说明会公告，5月6日股价上涨2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633318317","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633318317?lang=zh_cn&edition=full","pubTime":"2026-05-06 17:36","pubTimestamp":1778060183,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，千红制药报收于7.19元，较前一交易日上涨2.71%，最新总市值为92.02亿元。该股当日开盘7.01元，最高7.36元，最低7.01元，成交额达1.68亿元，换手率为2.47%。千红制药于近日披露《关于举行2025年度报告网上说明会的公告》。公告显示，公司将于2026年5月8日15:00-16:00在全景网平台举行2025年度报告网上说明会，采用网络远程方式召开。公司将对普遍关注的问题在说明会上予以回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600027681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633900560","title":"千红制药：公司不存在应披露而未披露的重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2633900560","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633900560?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:39","pubTimestamp":1778056751,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)05月06日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘请问:现在公司有多少应报露但还没有披露的重要消息？千红制药回复：尊敬的投资者您好，根据公司最新公告及信息披露记录，公司目前不存在任何根据《深圳证券交易所股票上市规则》等有关规定应予以披露而未披露的重大事项。公司将持续严格遵守信息披露相关规定，确保信息发布的真实、准确、完整和公平。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600025055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631152151","title":"股市必读：千红制药（002550）4月29日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2631152151","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631152151?lang=zh_cn&edition=full","pubTime":"2026-04-30 04:36","pubTimestamp":1777495010,"startTime":"0","endTime":"0","summary":"截至2026年4月29日收盘，千红制药报收于7.09元，下跌0.28%，换手率1.19%，成交量11.23万手，成交额7985.95万元。董秘最新回复投资者： 从2025年公司的发展治理报告看到公司和天目湖健康研究院、昔关瑞等机构成立联合实验室是不是真的？当日关注点来自交易信息汇总：4月29日主力资金净流出970.83万元，散户资金净流入888.5万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000012882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395435","title":"30余家药企一季报出炉：有人狂赚有人亏 行业分化加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395435","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630395435?lang=zh_cn&edition=full","pubTime":"2026-04-27 19:29","pubTimestamp":1777289340,"startTime":"0","endTime":"0","summary":"近日，A股医药板块迎来一季度财报密集披露期，包括阳光诺和、华东医药、重药控股、圣诺生物、我武生物、一品红、丽珠集团、浙江医药、济川药业、科源制药、千红制药等在内的超30家药企集中交出第一季度成绩单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604273720459429.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604273720459429.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0191","BK0216","BK0071","BK0196","BK0183","301281","688621","688117","06978","BK0188","BK0028","300723","BK1161","002550","BK0250","BK0209","LU2328871848.SGD","BK0187","BK0132","BK0175","BK0239","000950","LU1969619763.USD","600216","000963","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630356449","title":"千红制药：公司可转债项目尚处于有序推进过程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2630356449","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630356449?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:33","pubTimestamp":1777260819,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药04月27日在投资者关系平台上答复投资者关心的问题。千红制药回复：尊敬的投资者，您好，公司于2024年12月召开2024年第三次临时股东大会审议通过的可转债预案，已于2025年12月召开2025年第二次临时股东会审议通过了修订稿，公司可转债项目尚处于有序推进过程中，后续进展将依法及时公告，感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700017540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630336937","title":"股市必读：千红制药年报 - 第四季度单季净利润同比下降66.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630336937","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630336937?lang=zh_cn&edition=full","pubTime":"2026-04-27 03:27","pubTimestamp":1777231631,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告千红制药2025年年报显示，当年度公司主营收入15.71亿元，同比上升2.95%；归母净利润3.99亿元，同比上升12.01%；扣非净利润2.83亿元，同比上升5.33%；其中2025年第四季度，公司单季度主营收入3.56亿元，同比上升11.81%；单季度归母净利润1556.93万元，同比下降66.48%；单季度扣非净利润1229.98万元，同比下降69.83%；负债率10.43%，投资收益1159.24万元，财务费用480.94万元，毛利率58.36%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629127814","title":"千红制药(002550)3月31日股东户数7.45万户，较上期增加2.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629127814","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629127814?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:36","pubTimestamp":1777023368,"startTime":"0","endTime":"0","summary":"证券之星消息，近日千红制药披露，截至2026年3月31日公司股东户数为7.45万户，较12月31日增加1768.0户，增幅为2.43%。在化学制药行业个股中，千红制药股东户数高于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.51万户。从股价来看，2025年12月31日至2026年3月31日，千红制药区间跌幅为2.8%，在此期间股东户数增加1768.0户，增幅为2.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400053112.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629557398","title":"千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629557398","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629557398?lang=zh_cn&edition=full","pubTime":"2026-04-23 23:33","pubTimestamp":1776958392,"startTime":"0","endTime":"0","summary":"智通财经APP讯，千红制药(002550.SZ)发布2026年第一季度报告，第一季度，公司实现营业收入3.58亿元，同比下降20.58%。归属于上市公司股东的净利润8505.51万元，同比下降47.16%。归属于上市公司股东的扣除非经常性损益的净利润7740.74万元，同比下降27.60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433020.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"千红制药(002550.SZ)发布一季度业绩，归母净利润8505.51万元，同比下降47.16%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629100079","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2629100079","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629100079?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:06","pubTimestamp":1776927979,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月23日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘:为什么你在前期回复公司的创新药106项目的临床进度，说法和监管部门窗口实际批准公布临床存前后不一、自相矛盾？是否涉嫌故意误导投资者？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300037287.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628717097","title":"千红制药：公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中","url":"https://stock-news.laohu8.com/highlight/detail?id=2628717097","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628717097?lang=zh_cn&edition=full","pubTime":"2026-04-20 15:36","pubTimestamp":1776670567,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)04月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘:你以前在互动易提问回复中说106创新药正在和CDE沟通申请进行三期临床试验，那么在长达一年的时间里开了几次沟通会议、有没有沟通记录和监管部门给出了什么切实可行建议？千红制药回复：尊敬的投资者您好，公司原创一类新药QHRD106项目正处于科学、有序地推进临床试验进程中，相关进展将严格遵循法规披露要求。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000015018.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002550"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779151182866,"stockEarnings":[{"period":"1week","weight":-0.0558},{"period":"1month","weight":-0.1298},{"period":"3month","weight":-0.1231},{"period":"6month","weight":-0.2073},{"period":"1year","weight":0.1323},{"period":"ytd","weight":-0.1387}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0198},{"period":"3month","weight":0.0121},{"period":"6month","weight":0.0468},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.041}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"常州千红生化制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"74524人(较上一季度增加2.43%)","perCapita":"12630股","listingDate":"2011-02-18","address":"江苏省常州市新北区云河路518号","registeredCapital":"127980万元","survey":" 常州千红生化制药股份有限公司的主营业务是生物医药品的研发、生产和销售。公司的主要产品是常生千红、千红怡诺、千红怡达、千红怡那、怡开、千红怡美、常生、千红怡甘。","listedPrice":32},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"千红制药,002550,千红制药股票,千红制药股票老虎,千红制药股票老虎国际,千红制药行情,千红制药股票行情,千红制药股价,千红制药股市,千红制药股票价格,千红制药股票交易,千红制药股票购买,千红制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"千红制药(002550)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供千红制药(002550)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}